DOI: 10.1146/annurev-pharmtox-010716-104558

¤ OpenAccess: Green

This work has “Green” OA status. This means it may cost money to access on the publisher landing page, but there is a free copy in an OA repository.

Aptamers as Therapeutics

Shahid M. Nimjee,Rebekah R. White,Richard C. Becker,Bruce A. Sullenger

Aptamer

Systematic evolution of ligands by exponential enrichment

SELEX Aptamer Technique

2017

Aptamers are single-stranded nucleic acid molecules that bind to and inhibit proteins and are commonly produced by systematic evolution of ligands by exponential enrichment (SELEX). Aptamers undergo extensive pharmacological revision, which alters affinity, specificity, and therapeutic half-life, tailoring each drug for a specific clinical need. The first therapeutic aptamer was described 25 years ago. Thus far, one aptamer has been approved for clinical use, and numerous others are in preclinical or clinical development. This review presents a short history of aptamers and SELEX, describes their pharmacological development and optimization, and reviews potential treatment of diseases including visual disorders, thrombosis, and cancer.

Cite this:

Generate Citation

“Aptamers as Therapeutics” is a paper by Shahid M. Nimjee Rebekah R. White Richard C. Becker Bruce A. Sullenger published in 2017. It has an Open Access status of “green”. You can read and download a PDF Full Text of this paper here.